Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Welcome and Introduction to Vi3C

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Jun
25
Today In Oncology
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
Multi-Cancer Early Detection Test Performs Well in Real-World Asian Cohort
Subgroup Analysis Demonstrates Efficacy of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo